MA40957A - Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies - Google Patents

Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies

Info

Publication number
MA40957A
MA40957A MA040957A MA40957A MA40957A MA 40957 A MA40957 A MA 40957A MA 040957 A MA040957 A MA 040957A MA 40957 A MA40957 A MA 40957A MA 40957 A MA40957 A MA 40957A
Authority
MA
Morocco
Prior art keywords
treat diseases
biosynthesis inhibitors
heparane
sulphate
heparane sulphate
Prior art date
Application number
MA040957A
Other languages
English (en)
Inventor
Shripad Bhagwat
Gregory R Luedtke
Mark Spyvee
Bing Wang
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MA40957A publication Critical patent/MA40957A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA040957A 2014-10-09 2015-10-07 Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies MA40957A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462062036P 2014-10-09 2014-10-09

Publications (1)

Publication Number Publication Date
MA40957A true MA40957A (fr) 2017-09-19

Family

ID=55653801

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040957A MA40957A (fr) 2014-10-09 2015-10-07 Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies

Country Status (16)

Country Link
US (1) US20190151312A1 (fr)
EP (1) EP3204009A4 (fr)
JP (1) JP2017530991A (fr)
KR (1) KR20170072242A (fr)
CN (1) CN107106561A (fr)
AR (1) AR102213A1 (fr)
AU (1) AU2015330846A1 (fr)
BR (1) BR112017006705A2 (fr)
CA (1) CA2963607A1 (fr)
IL (1) IL251497A0 (fr)
MA (1) MA40957A (fr)
MX (1) MX2017004618A (fr)
RU (1) RU2017115305A (fr)
TW (1) TW201629051A (fr)
WO (1) WO2016057834A1 (fr)
ZA (1) ZA201703003B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3348547T (pt) 2015-09-11 2020-10-12 Sumitomo Dainippon Pharma Co Ltd Derivados de benzimidazole como inibidores de nav 1.7 (canal de sódio, controlado por tensão, tipo ix, subunidade alfa (scn9a)) para o tratamento de dor, disúria e esclerose múltipla
WO2018177781A1 (fr) 2017-03-28 2018-10-04 Basf Se Composés pesticides
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
WO2019000683A1 (fr) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Inhibiteur de protéine kinase associée à rho, composition pharmaceutique contenant celui-ci, son procédé de préparation et ses applications
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
CN107445899A (zh) * 2017-07-19 2017-12-08 枣庄学院 一种苯并咪唑类化合物及其制备方法
JP7399848B2 (ja) * 2017-09-01 2023-12-18 カドモン コーポレイション,リミティド ライアビリティ カンパニー Rho関連コイルドコイル含有プロテインキナーゼの阻害剤
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll相互作用のエキソ-アザスピロ阻害剤
CN108997343A (zh) * 2018-04-17 2018-12-14 丁敏 一种治疗小儿热性惊厥的药物组合物的制备方法
CN108794470B (zh) * 2018-07-25 2020-06-26 上海毕得医药科技有限公司 一种6-肼基-1H-吡唑并[3,4-b]吡啶及其下游产品的合成方法
US11053501B2 (en) 2018-11-30 2021-07-06 The Penn State Research Foundation Methods of treating neurodegenerative disease by inhibiting N-deacetylase N-sulfotransferase
ES3029360T3 (en) * 2019-11-15 2025-06-24 Ildong Pharmaceutical Co Ltd Glp-1 receptor agonist and use thereof
AU2020405068A1 (en) 2019-12-18 2022-07-07 Stinginn Llc Substituted 1,2, 4-triazoles and methods of use
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
JP2026524104A (ja) * 2023-06-28 2026-07-17 サイロ プロプリエタリー リミテッド 化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2316831T3 (da) * 2002-11-21 2013-06-10 Novartis Ag 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
WO2009066084A1 (fr) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2-morpholinopyrimidines et leur utilisation en tant qu'inhibiteurs de kinase pi3
AU2011271462A1 (en) * 2010-06-30 2013-01-10 Amgen Inc. Nitrogen containing heterocyclic compounds as PIK3 -delta inhibitors

Also Published As

Publication number Publication date
ZA201703003B (en) 2018-04-25
JP2017530991A (ja) 2017-10-19
AU2015330846A1 (en) 2017-05-18
RU2017115305A (ru) 2018-11-14
EP3204009A1 (fr) 2017-08-16
KR20170072242A (ko) 2017-06-26
CA2963607A1 (fr) 2016-04-14
US20190151312A1 (en) 2019-05-23
CN107106561A (zh) 2017-08-29
WO2016057834A1 (fr) 2016-04-14
TW201629051A (zh) 2016-08-16
EP3204009A4 (fr) 2018-05-23
MX2017004618A (es) 2017-10-23
BR112017006705A2 (pt) 2017-12-26
AR102213A1 (es) 2017-02-15
IL251497A0 (en) 2017-05-29
WO2016057834A9 (fr) 2017-04-13

Similar Documents

Publication Publication Date Title
IL271085A (en) Bacteria for the treatment of disorders
IL257978A (en) Use of pasteurized acrementia to treat metabolic diseases
IL256216A (en) A transgenic bacterium for the treatment of disorders in which there is a breakdown of a split amino acid chain
ZA201801019B (en) Compounds useful for treating disorders related to kit and pdgfr
ZA201801881B (en) Compounds and compositions useful for treating disorders related to ntrk
IL259164A (en) Compounds and compositions useful for treating disorders related to ntrk
IL255831A (en) Inhibitors of bruton's tyrosine kinase
ZA201703003B (en) Heparan sulfate biosynthesis inhibitors for the treatment of diseases
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
IL250085A0 (en) New compounds of proton tyrosine kinase inhibitor
IL244492A0 (en) Broton tyrosine kinase inhibitors
EP4282479A3 (fr) Utilisation de pridopidine pour traiter la dépression ou l'anxiété
EP3174874A4 (fr) Sels de berbérine, sels ursodésoxycholiques et des combinaisons, des procédés de préparation et d'application correspondants
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
EP2968801A4 (fr) Procédés pour traiter des maladies respiratoires et formulations pour la mise en oeuvre de ceux-ci
SG10201802098UA (en) Compositions and methods of use for treating metabolic disorders
HUE062714T2 (hu) SGLT2 inhibitorok kutyafélék anyagcserezavarainak kezelésére
MA56412A (fr) Thérapie par l'arn messager pour le traitement des maladies articulaires
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
IL256206A (en) Mct4 inhibitors for treating disease
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
SG11201608397UA (en) Glyt1 inhibitors for use in the treatment of hematological disorders
IL259153A (en) Use of proteasome inhibitors to treat ocular disorders
EP3204028A4 (fr) Composition synergique pour l'arthrose
EP3384005A4 (fr) Supplémentation en arginine pour améliorer l'efficacité des acétogènes de fermentation gazeuse